omeprazole has been researched along with Sclerosis, Systemic in 14 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-five patients with systemic sclerosis and severe gastro-oesophageal reflux disease were treated with 20-80 mg omeprazole daily for up to 5 years." | 9.07 | Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. ( Hage, E; Hendel, J; Hendel, L; Stentoft, P, 1992) |
| "Twice-daily dosing of proton pump inhibitor (PPI), the standard therapy for gastro-oesophageal reflux disease (GERD), is an effective therapy for GERD in SSc." | 6.84 | Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. ( Chunlertrith, K; Foocharoen, C; Mahakkanukrauh, A; Mairiang, P; Namvijit, S; Nanagara, R; Suwannaroj, S; Wantha, O, 2017) |
| "Twenty-five patients with systemic sclerosis and severe gastro-oesophageal reflux disease were treated with 20-80 mg omeprazole daily for up to 5 years." | 5.07 | Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. ( Hage, E; Hendel, J; Hendel, L; Stentoft, P, 1992) |
| "Proton pump inhibitor (PPI) twice daily dosing is a standard therapy for gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc) but there is no data on its response rate or the predictors of PPI-partial response GERD." | 2.94 | Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study. ( Chunlertrith, K; Foocharoen, C; Mahakkanukrauh, A; Mairiang, P; Namvijit, S; Nanagara, R; Suwannaroj, S; Wantha, O, 2020) |
| "Twice-daily dosing of proton pump inhibitor (PPI), the standard therapy for gastro-oesophageal reflux disease (GERD), is an effective therapy for GERD in SSc." | 2.84 | Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. ( Chunlertrith, K; Foocharoen, C; Mahakkanukrauh, A; Mairiang, P; Namvijit, S; Nanagara, R; Suwannaroj, S; Wantha, O, 2017) |
| "Gastro-oesophageal reflux disease (GERD) is an important problem in systemic sclerosis due to impaired salivation and oesophageal function." | 2.73 | Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial. ( Brühlmann, P; Distler, O; Fox, M; Fried, M; Halim, S; Janiak, P; Menne, D; Schwizer, W; Thumshirn, M, 2007) |
| "In patients with systemic sclerosis peristaltic abnormalities may delay gastric emptying, giving rise to bacterial overgrowth, including possibly Helicobacter pylori (HP)." | 1.29 | Helicobacter pylori in patients with systemic sclerosis: detection with the 13C-urea breath test and eradication. ( Goerz, G; Humfeld, S; Reinauer, H; Reinauer, S; Ruzicka, T; Susanto, F, 1994) |
| "The hydroxyproline concentration was significantly increased (P less than 0." | 1.28 | Hydroxyproline in the oesophageal mucosa of patients with progressive systemic sclerosis during omeprazole-induced healing of reflux oesophagitis. ( Hendel, L, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 7 (50.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Foocharoen, C | 2 |
| Chunlertrith, K | 2 |
| Mairiang, P | 2 |
| Mahakkanukrauh, A | 2 |
| Suwannaroj, S | 2 |
| Namvijit, S | 2 |
| Wantha, O | 2 |
| Nanagara, R | 2 |
| Balbir-Gurman, A | 1 |
| Brook, OR | 1 |
| Chermesh, I | 1 |
| Braun-Moscovici, Y | 1 |
| Hage, E | 2 |
| Hendel, L | 4 |
| Gustafsen, J | 1 |
| Hendel, J | 2 |
| Janiak, P | 1 |
| Thumshirn, M | 1 |
| Menne, D | 1 |
| Fox, M | 1 |
| Halim, S | 1 |
| Fried, M | 1 |
| Brühlmann, P | 1 |
| Distler, O | 1 |
| Schwizer, W | 1 |
| Gough, A | 1 |
| Andrews, D | 1 |
| Bacon, PA | 1 |
| Emery, P | 1 |
| Handa, Y | 1 |
| Ietomi, K | 1 |
| Sakimura, K | 1 |
| Miyoshi, K | 1 |
| Reinauer, S | 1 |
| Goerz, G | 1 |
| Ruzicka, T | 1 |
| Susanto, F | 1 |
| Humfeld, S | 1 |
| Reinauer, H | 1 |
| Shoenut, JP | 1 |
| Wieler, JA | 1 |
| Micflikier, AB | 1 |
| Stentoft, P | 1 |
| Hostein, J | 1 |
| Li, V | 1 |
| Carpentier, P | 1 |
| Fournet, J | 1 |
| Olive, A | 1 |
| Maddison, PJ | 1 |
| Davis, M | 1 |
| Svejgaard, E | 1 |
| Walsøe, I | 1 |
| Kieffer, M | 1 |
| Stenderup, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis[NCT01878526] | Phase 3 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Unit scale 0-48 was applied for an outcome measurement of the frequency of symptoms. The unit scale 0 was no symptom and scale 48 was usual symptom of GERD. The changing of the frequency of symptoms was the changing of the unit scale before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 4.6 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 4.7 |
VAS scale 0-100 was applied for an outcome measurement of the quality of life. The VAS scale 0 was the worst quality of life and scale 100 was the best quality of life. The changing of the quality of life was the changing of VAS of quality of life before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | VAS (100) (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 75.7 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 76.1 |
VAS scale 0-100 was applied for an outcome measurement of the severity of regurgitation. The VAS scale 0 was no symptoms of regurgitation and scale 100 was a maximum symptom of regurgitation. The changing of the severity of regurgitation was the changing of VAS before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | VAS (100) (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 24.9 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 23.1 |
VAS scale 0-100 was applied for an outcome measurement of the severity of heart burn. The VAS scale 0 was no symptoms of heart burn and scale 100 was a maximum symptom of heart burn. The changing of the severity of heart burn was the changing of VAS before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | VAS (100) (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 17.9 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 17.2 |
(NCT01878526)
Timeframe: 4 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Overall Systemic Sclerosis With GERD (Before Randomization) | 59 |
1 review available for omeprazole and Sclerosis, Systemic
| Article | Year |
|---|---|
Pneumatosis cystoides intestinalis in scleroderma-related conditions.
Topics: Abdomen, Acute; Adrenal Cortex Hormones; Adult; Aged; Connective Tissue Diseases; Diagnosis, Differe | 2012 |
4 trials available for omeprazole and Sclerosis, Systemic
| Article | Year |
|---|---|
Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Gastroesophageal Reflux; Human | 2020 |
Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
Topics: Adult; Aged; Alginates; Antiemetics; Domperidone; Drug Therapy, Combination; Female; Gastroesophagea | 2017 |
Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
Topics: Aged; Anti-Ulcer Agents; Cross-Over Studies; Drug Therapy, Combination; Female; Gastroesophageal Ref | 2007 |
Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis.
Topics: Adult; Aged; Barrett Esophagus; Drug Administration Schedule; Esophageal Motility Disorders; Esophag | 1992 |
9 other studies available for omeprazole and Sclerosis, Systemic
| Article | Year |
|---|---|
Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Topics: Achlorhydria; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cell Division; Drug Administration Schedul | 2003 |
Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma.
Topics: Adult; Aged; Anti-Ulcer Agents; Bacteria; Breath Tests; Female; Humans; Intestine, Small; Middle Age | 1995 |
[A case of multiple gastric hyperplastic polyps: onset during omeprazole therapy in scleroderma patient].
Topics: Aged; Esophagitis, Peptic; Female; Humans; Hyperplasia; Omeprazole; Polyps; Scleroderma, Systemic; S | 1994 |
Helicobacter pylori in patients with systemic sclerosis: detection with the 13C-urea breath test and eradication.
Topics: Adult; Aged; Amoxicillin; Breath Tests; Carbon Isotopes; Drug Therapy, Combination; Dyspepsia; Esoph | 1994 |
The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole.
Topics: Adult; Aged; Deglutition Disorders; Dose-Response Relationship, Drug; Esophagus; Female; Gastroesoph | 1993 |
Hydroxyproline in the oesophageal mucosa of patients with progressive systemic sclerosis during omeprazole-induced healing of reflux oesophagitis.
Topics: Adult; Aged; Biopsy; Esophagitis, Peptic; Esophagus; Female; Fibrosis; Humans; Hydroxyproline; Male; | 1991 |
[Omeprazole: crucial progress in the treatment of esophagitis in progressive systemic scleroderma].
Topics: Esophagitis; Female; Humans; Middle Aged; Omeprazole; Scleroderma, Systemic | 1991 |
Treatment of oesophagitis in scleroderma with omeprazole.
Topics: Esophagitis; Humans; Omeprazole; Pilot Projects; Scleroderma, Systemic | 1989 |
Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole.
Topics: Adult; Aged; Antifungal Agents; Candidiasis; Esophageal Diseases; Esophagoscopy; Female; Fluconazole | 1988 |